|Company name||Medco Health Solutions Inc.|
|Live stock price||[stckqut]MHS[/stckqut]|
|P/E compared to competitors||Fair|
|Confident Investor Rating||Fair|
|Target stock price (TWCA growth scenario)||$67.03|
|Target stock price (averages with growth)||$90.46|
|Target stock price (averages with no growth)||$75.84|
|Target stock price (manual assumptions)||$78.42|
The following company description is from Google Finance: http://www.google.com/finance?q=mhs
Medco Health Solutions, Inc. (Medco) is a healthcare company. It provides clinically-driven pharmacy services designed to improve the quality of care and lower total healthcare costs for private and public employers, health plans, labor unions and government agencies of all sizes, and for individuals served by Medicare Part D Prescription Drug Plans. During the fiscal year ended December 26, 2009 (fiscal 2009), the Company administered 695 million prescriptions. In January 2010, the Company completed the acquisition of DNA Direct Inc. In April 2008, Medco acquired a majority interest in Europa Apotheek Venlo B.V. (Europa Apotheek), which provides mail-order pharmacy services in Germany. In 2009, Medco formed a joint venture with United Drug plc, a pan-European healthcare provider, to provide home-based pharmacy care services in the United Kingdom for patients covered by the country’s National Health Service.
Confident Investor comments: At this time, I think that a Confident Investor can cautiously invest in this stock as long as the price is correct. Most of the fundamentals of this company are good but there are some concerns.